Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE HUMAN MICROBIOME MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 GLOBAL HUMAN MICROBIOME MARKET ANALYSIS
4.4 GUT MICROBIOME AND DIAGNOSTIC
5 EPIDEMIOLOGY
5.1 EPIDEMIOLOGY CANCER
5.2 EPIDEMIOLOGY DERMATOLOGICAL DISORDERS
5.3 EPIDEMIOLOGY GASTRIC DISORDERS
5.4 EPIDEMIOLOGY IMMUNE DISORDERS
5.5 EPIDEMIOLOGY METABOLIC DISORDERS
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
7 INDUSTRY INSIGHT
7.1 PATENT ANALYSIS
7.2 PATENT FLOW DIAGRAM
8 REGULATORY FRAMEWORKS
8.1 UNITED STATES
8.2 EUROPE
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING PREVALENCE OF LIFESTYLE AND CHRONIC DISEASES
9.1.2 HUMAN MICROBIOME THERAPEUTIC DEVELOPMENT FOR DISEASE TREATMENT
9.1.3 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING
9.2 RESTRAINTS
9.2.1 BARRIERS PROVING THE CAUSAL LINK BETWEEN DYSBIOSIS AND DISEASES
9.2.2 LACK OF TECHNOLOGY EXPERTISE
9.3 OPPORTUNITIES
9.3.1 RISE IN HEALTHCARE EXPENDITURE
9.3.2 INCREASING RESEARCH AND DEVELOPMENT
9.4 CHALLENGE
9.4.1 RISK ASSOCIATED WITH HUMAN MICROBIOME PRODUCTS
10 EUROPE HUMAN MICROBIOME MARKET, BY PRODUCT
10.1 OVERVIEW
10.2 PROBIOTICS
10.2.1 BRANDED
10.2.1.1 OPTIPAC-PREBIOTICS FIBRE
10.2.1.2 ENZYMEDICA-PREBIOTICS DRINK MIX
10.2.1.3 SWEETBIOTIX
10.2.1.4 OTHERS
10.2.2 GENERICS
10.3 PREBIOTICS
10.3.1 BRANDED
10.3.1.1 BIOM PROBIOTIC
10.3.1.2 BIOM D FEND
10.3.1.3 FLORE GUT MICROBIOME TEST
10.3.1.4 REVITIFY
10.3.1.5 SYMBIOTIC YOGURT
10.3.1.6 SYMBIOTIC
10.3.1.7 LPLDL
10.3.1.8 LPGOS
10.3.1.9 OTHERS
10.3.2 GENERICS
10.4 SUPPLEMENTS
10.4.1 CHOLBIOME
10.4.2 LPGOS
10.4.3 WELL BIOME
10.4.4 FLORE BOOM
10.4.5 FLORE DEFENCE
10.4.6 FLORE BALANCE
10.4.7 BIOM
10.4.8 REVITIFY
10.4.9 FLORE
10.4.10 BIOM D FEND
10.4.11 SLIM BIOME
10.4.12 OTHERS
10.5 DIAGNOSTICS TESTS
10.5.1 FLORE GUT MICROBIOME TEST
10.5.2 FLORE 360
10.5.3 BIOME MICROBIOME TEST
10.5.4 SUPER GUT MICROBIOME HEALTH TEST
10.5.5 HEALTH INTELLIGENCE TEST
10.5.6 GUT INTELLIGENCE TEST
10.5.7 X MARKER
10.5.8 ATLAS MICROBIOME TEST
10.5.9 1TEST 1
10.5.10 LIFE KIT
10.5.11 FOR A
10.5.12 OTHERS
10.6 DRUGS
10.6.1 OXABACT
10.6.2 SINTAX
10.6.3 SYNBIOTIC YOGURT
10.6.4 SYNBIOTIC 7
10.6.5 MICRORX
10.6.6 SLIM BIOME
10.6.7 SLIM BIOME MEDICAL
10.6.8 LPLDL
10.6.9 CHOLBIOME
10.6.10 OTHERS
10.7 FECAL MICROBIOTA TRANSPLANT
10.8 OTHERS
11 EUROPE HUMAN MICROBIOME MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 THERAPEUTIC
11.2.1 SINGLE STRAIN OR MULTI-STRAIN CONSORTIA
11.2.2 LIQUID OR DRIED BULK DRUG SUBSTANCE
11.2.3 SOLID ORAL DOSE
11.2.4 OTHERS
11.3 DIAGNOSTIC
11.3.1 IRRITABLE BOWEL SYNDROME
11.3.2 LEAKY GUT SYNDROME
11.3.3 DIABETES
11.3.4 BACTERIAL VAGINOSIS
11.3.5 GINGITIVIS
11.3.6 TRICHOMONIASIS
11.3.7 VAGINAL CANDIDIASIS
12 EUROPE HUMAN MICROBIOME MARKET, BY DISEASE
12.1 OVERVIEW
12.2 INFECTIOUS DISEASE
12.2.1 HELICOBACTER PYLORI
12.2.2 C. DIFFICILE INFECTIONS
12.2.3 BACTERIAL VAGINOSIS
12.2.4 OTHERS
12.3 GASTROINTESTINAL DISORDERS
12.4 C. DIFFICILE INFECTION
12.5 METABOLIC DISORDER
12.5.1 DIABETES
12.5.2 OBESITY
12.5.3 ENDOCRINE
12.5.4 NON ALCOHOLIC LIVER DISEASE
12.6 AUTOIMMUNE DISORDER
12.7 CANCER
12.8 MENTAL DISORDER
12.9 DERMATOLOGICAL DISORDERS
12.9.1 ATOPIC DERMATITIS
12.9.2 ROSACEA
12.9.3 ACNE
12.9.4 OTHERS
12.1 PRIMARY HYPEROXYUREASOLUTION-PHASE
12.11 OTHERS
13 U.S. HUMAN MICROBIOME MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 GENOMICS
13.2.1 SEQUENCING
13.2.1.1 16S RRNA SEQUENCING METHOD
13.2.1.2 SHOTGUN METAGENOMICS SEQUENCING
13.2.1.3 WHOLE GENOME SEQUENCING
13.2.1.4 OTHER
13.2.2 POLYMERASE CHAIN REACTION
13.2.3 OTHER GENOMIC TECHNIQUES
13.2.4 ORGAN TRANSPLANTATION
13.2.5 OTHER CLINICAL APPLICATION
13.3 PROTEOMICS
13.3.1 EXPRESSION PROTEOMICS
13.3.2 FUNCTIONAL PROTEOMICS
13.3.3 STRUCTURAL PROTEOMICS
13.4 METABOLIMICS
13.4.1 TARGETED ANALYSIS
13.4.2 METABOLITE PROFILING
13.4.3 METABOLIC FINGERPRINTING
14 EUROPE HUMAN MICROBIOME MARKET, BY TYPE
14.1 OVERVIEW
14.2 SMALL MOLECULE
14.3 BIOLOGIC
15 EUROPE HUMAN MICROBIOME MARKET, BY END USER
15.1 OVERVIEW
15.2 ONLINE PHARMACIES
15.3 HYPERMARKET & SUPERMARKET
15.4 RETAIL PHARMACIES
15.5 HOSPITAL PHARMACIES
15.6 CLINICS
15.7 OTHERS
16 EUROPE HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL SALES
16.3 DIRECT TENDERS
17 EUROPE HUMAN MICROBIOME MARKET, BY COUNTRY
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 U.K.
17.1.4 ITALY
17.1.5 SPAIN
18 EUROPE HUMAN MICROBIOME MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 COMPANY PROFILE
19.1 OPTIBIOTIX HEALTH PLC
19.1.1 COMPANY SNAPSHOT
19.1.2 PRODUCT PORTFOLIO
19.1.3 RECENT DEVELOPMENT
19.2 MERCK KGAA
19.2.1 COMPANY SNAPSHOT
19.2.2 PRODUCT PORTFOLIO
19.2.3 RECENT DEVELOPMENTS
19.3 FINCH THERAPEUTICS GROUP, INC
19.3.1 COMPANY SNAPSHOT
19.3.2 PIPELINE PRODUCT PORTFOLIO
19.3.3 RECENT DEVELOPMENT
19.4 FERRING B.V.
19.4.1 COMPANY SNAPSHOT
19.4.2 PIPELINE PRODUCT PORTFOLIO
19.4.3 RECENT DEVELOPMENTS
19.5 ATLAS BIOMED GROUP LIMITED
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 ENTEROME
19.6.1 COMPANY SNAPSHOT
19.6.2 PIPELINE PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENTS
19.7 ASSEMBLY BIOSCIENCES, INC.
19.7.1 COMPANY SNAPSHOT
19.7.2 PIPELINE PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BIOMX
19.8.1 COMPANY SNAPSHOT
19.8.2 PIPELINE PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENTS
19.9 EMBION TECHNOLOGIES S.A.
19.9.1 COMPANY SNAPSHOT
19.9.2 PIPELINE PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 EVELO BIOSCIENCES, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PIPELINE PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 FLIGHTPATH BIOSCIENCES, INC.
19.11.1 COMPANY SNAPSHOT
19.11.2 PIPELINE PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 GNUBIOTICS SCIENCES
19.12.1 COMPANY SNAPSHOT
19.12.2 PIPELINE PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENTS
19.13 IMMURON
19.13.1 COMPANY SNAPSHOT
19.13.2 PIPELINE PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 LUXIA SCIENTIFIC
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 METABIOMICS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 OSEL INC
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 OXTHERA.
19.17.1 COMPANY SNAPSHOT
19.17.2 PIPELINE PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 SECOND GENOME
19.18.1 COMPANY SNAPSHOT
19.18.2 PIPELINE PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENTS
19.19 SERES THERAPEUTICS
19.19.1 COMPANY SNAPSHOT
19.19.2 PIPELINE PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 SUN GENOMICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
19.21 SYNTHETIC BIOLOGICS, INC..
19.21.1 COMPANY SNAPSHOT
19.21.2 PIPELINE PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENTS
19.22 SYNLOGIC
19.22.1 COMPANY SNAPSHOT
19.22.2 PIPELINE PRODUCT PORTFOLIO
19.22.3 RECENT DEVELOPMENTS
19.23 VEDANTA BIOSCIENCES, INC.
19.23.1 COMPANY SNAPSHOT
19.23.2 PIPELINE PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 VIOME LIFESCIENCES, US
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENT
19.25 YSOPIA BIOSCIENCE
19.25.1 COMPANY SNAPSHOT
19.25.2 PIPELINE PRODUCT PORTFOLIO
19.25.3 RECENT DEVELOPMENT
19.26 4D PHARMA PLC
19.26.1 COMPANY SNAPSHOT
19.26.2 PRODUCT PORTFOLIO
19.26.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 PATENT ANALYSIS
TABLE 2 EUROPE HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 4 EUROPE BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 7 EUROPE SUPPLEMENTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 8 EUROPE DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 9 EUROPE DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 10 EUROPE HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 16 EUROPE DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 18 EUROPE GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 19 EUROPE SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 20 EUROPE PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 21 EUROPE METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 EUROPE HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 EUROPE HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 EUROPE HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 25 EUROPE HUMAN MICROBIOME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 26 GERMANY HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 GERMANY PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 28 GERMANY BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 29 GERMANY PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 30 GERMANY BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 31 GERMANY DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 32 GERMANY DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 GERMANY SUPPLEMENT IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 34 GERMANY HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 35 GERMANY THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 36 GERMANY DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 37 GERMANY HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 38 GERMANY DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 39 GERMANY METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 40 GERMANY INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 41 GERMANY HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 42 GERMANY GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 43 GERMANY SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 44 GERMANY PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 45 GERMANY METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 46 GERMANY HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 GERMANY HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 GERMANY HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 49 FRANCE HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 50 FRANCE PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 51 FRANCE BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 52 FRANCE PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 53 FRANCE BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 FRANCE DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 55 FRANCE DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 56 FRANCE SUPPLEMENT IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 FRANCE HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 FRANCE THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 FRANCE DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 FRANCE HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 63 FRANCE INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 65 FRANCE GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 66 FRANCE SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 67 FRANCE PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 68 FRANCE METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 69 FRANCE HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 FRANCE HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.K. HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 73 U.K. PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 74 U.K. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 75 U.K. PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 76 U.K. BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 77 U.K. DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 78 U.K. DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 79 U.K. SUPPLEMENT IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 U.K. HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 U.K. THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 U.K. DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 U.K. HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 84 U.K. DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 85 U.K. METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 86 U.K. INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 87 U.K. HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 U.K. GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 U.K. SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 90 U.K. METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 91 U.K. HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.K. HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.K. HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 ITALY HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 95 ITALY PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 96 ITALY BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 97 ITALY PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 98 ITALY BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 99 ITALY DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 100 ITALY DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 101 ITALY SUPPLEMENT IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 102 ITALY HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 ITALY THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 104 ITALY DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 105 ITALY HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 106 ITALY DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 107 ITALY METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 108 ITALY INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 109 ITALY HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 110 ITALY GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 111 ITALY SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 112 ITALY PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 113 ITALY METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 114 ITALY HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 ITALY HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 ITALY HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 SPAIN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 118 SPAIN PROBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 119 SPAIN BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 120 SPAIN PREBIOTICS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 SPAIN BRANDED IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 122 SPAIN DIAGNOSTICS TESTS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 123 SPAIN DRUGS IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 124 SPAIN SUPPLEMENT IN HUMAN MICROBIOME MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 125 SPAIN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 126 SPAIN THERAPEUTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 127 SPAIN DIAGNOSTIC IN HUMAN MICROBIOME MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 128 SPAIN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 129 SPAIN DERMATOLOGICAL DISORDERS IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 130 SPAIN METABOLIC DISORDER IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 131 SPAIN INFECTIOUS DISEASE IN HUMAN MICROBIOME MARKET, BY DISEASE, 2020-2029 (USD MILLION)
TABLE 132 SPAIN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 133 SPAIN GENOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 134 SPAIN SEQUENCING IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 135 SPAIN PROTEOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 136 SPAIN METABOLOMICS IN HUMAN MICROBIOME MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 137 SPAIN HUMAN MICROBIOME MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 SPAIN HUMAN MICROBIOME MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 SPAIN HUMAN MICROBIOME MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 2 EUROPE HUMAN MICROBIOME MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE HUMAN MICROBIOME MARKET: DROC ANALYSIS
FIGURE 4 EUROPE HUMAN MICROBIOME MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE HUMAN MICROBIOME MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE HUMAN MICROBIOME MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE HUMAN MICROBIOME MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE HUMAN MICROBIOME MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE HUMAN MICROBIOME MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE HUMAN MICROBIOME MARKET: SEGMENTATION
FIGURE 11 INCREASING TECHNOLOGICAL ADVANCEMENTS IN METAGENOMICS AND NEXT-GENERATION SEQUENCING ARE EXPECTED TO DRIVE THE EUROPE HUMAN MICROBIOME MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 PROBIOTICS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE HUMAN MICROBIOME MARKET IN 2022 & 2029
FIGURE 13 PATENT FLOW DIAGRAM FOR DRUGS IN THE EUROPE
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE HUMAN MICROBIOME MARKET
FIGURE 15 EUROPE HUMAN MICROBIOME MARKET: BY PRODUCT, 2021
FIGURE 16 EUROPE HUMAN MICROBIOME MARKET: BY PRODUCT, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE HUMAN MICROBIOME MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 18 EUROPE HUMAN MICROBIOME MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 19 EUROPE HUMAN MICROBIOME MARKET: BY APPLICATION, 2021
FIGURE 20 EUROPE HUMAN MICROBIOME MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE HUMAN MICROBIOME MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 22 EUROPE HUMAN MICROBIOME MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 23 EUROPE HUMAN MICROBIOME MARKET: BY DISEASE, 2021
FIGURE 24 EUROPE HUMAN MICROBIOME MARKET: BY DISEASE, 2022-2029 (USD MILLION)
FIGURE 25 EUROPE HUMAN MICROBIOME MARKET: BY DISEASE, CAGR (2022-2029)
FIGURE 26 EUROPE HUMAN MICROBIOME MARKET: BY DISEASE, LIFELINE CURVE
FIGURE 27 EUROPE HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2021
FIGURE 28 EUROPE HUMAN MICROBIOME MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 29 EUROPE HUMAN MICROBIOME MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 30 EUROPE HUMAN MICROBIOME MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 EUROPE HUMAN MICROBIOME MARKET: BY TYPE, 2021
FIGURE 32 EUROPE HUMAN MICROBIOME MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 33 EUROPE HUMAN MICROBIOME MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 34 EUROPE HUMAN MICROBIOME MARKET: BY TYPE, LIFELINE CURVE
FIGURE 35 EUROPE HUMAN MICROBIOME MARKET: BY END USER, 2021
FIGURE 36 EUROPE HUMAN MICROBIOME MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 EUROPE HUMAN MICROBIOME MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 EUROPE HUMAN MICROBIOME MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 EUROPE HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 EUROPE HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 EUROPE HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 EUROPE HUMAN MICROBIOME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 EUROPE HUMAN MICROBIOME MARKET: SNAPSHOT (2021)
FIGURE 44 EUROPE HUMAN MICROBIOME MARKET: BY COUNTRY (2021)
FIGURE 45 EUROPE HUMAN MICROBIOME MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 EUROPE HUMAN MICROBIOME MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 EUROPE HUMAN MICROBIOME MARKET: BY PRODUCT (2022-2029)
FIGURE 48 EUROPE HUMAN MICROBIOME MARKET: COMPANY SHARE 2021 (%)
